Crown Bioscience Partners With Turbine to Integrate AI and Organoid CRO Workflows

• Crown Bioscience has partnered with Turbine to integrate AI-driven prediction with organoid-based validation in translational oncology.

• The collaboration connects in silico modeling with CRO experimental workflows to improve efficiency, reduce costs, and accelerate drug discovery.

Crown Bioscience announced a strategic partnership with Turbine to integrate artificial intelligence–driven prediction with organoid-based validation, creating a connected workflow for translational oncology research. The collaboration combines Turbine’s in silico Virtual Assays with Crown Bioscience’s tumor organoid platforms to link computational insights with experimental validation.

Under the agreement, Turbine’s AI platform will simulate biological responses across multiple drug combinations and tumor models, generating predictive insights that can be tested using Crown Bioscience’s organoid assays. This approach is designed to improve the transition from hypothesis generation to laboratory validation within oncology drug discovery programs.

The partnership establishes a closed-loop system that connects prediction with validation, allowing researchers to prioritize experiments based on AI-generated insights. According to the companies, this integration can reduce experimental burden, improve predictive accuracy, and support faster decision-making across preclinical development.

From a CRO perspective, the collaboration enhances Crown Bioscience’s translational oncology services by embedding computational modeling into its experimental workflows. This integration enables sponsors to evaluate therapeutic strategies more efficiently and supports data-driven development across oncology pipelines.

“By connecting AI-driven prediction with organoid validation, we are enabling a more efficient and integrated approach to translational oncology, helping researchers move more effectively from hypothesis to experimental confirmation.”

Crown Bioscience’s Statement